Objective: Assess the effect of abatacept on progression of structural damage over 2 years in patients with rheumatoid arthritis who had an inadequate response to methotrexate. Methods: …

Jun 1, 2014 · In the AIM trial, treatment with ABA resulted in persistent radiographic inhibition over time, with almost half of all patients exhibiting no structural damage progression (change …

Apr 17, 2024 · We aimed to reveal the effect of abatacept (ABT) on atherosclerosis in rheumatoid arthritis (RA) patients, 3-year efficacy for arthritis, and safety in a population of older vs. …

Sep 27, 2010 · Reductions in the annual rate of structural damage progression observed in both patient populations suggest that abatacept has an increasing disease-modifying effect on …

Dec 17, 2007 · Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in …

In this article we discuss a recently published paper by Kremer et al. that reported 3-year data on safety, efficacy and radiographic progression in patients enrolled in a clinical trial of abatacept, …

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008;67:1084–9.

Oct 15, 2008 · Abatacept is a recombinant fusion protein that blocks the co-stimulatory signal mediated by the CD28-CD80/86 pathway, which is required for T-cell activation. Several …

demonstrated Abatacept (ABA), a T cell costimulation modulator, has and physical function, significant improvements has been shown in clinical reduce progression of structural damage …

Evaluate the safety and efficacy of longterm abatacept (ABA) treatment over 5 years in methotrexate (MTX)-refractory patients with rheumatoid arthritis (RA). Methods. Patients from …